• About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
Menu
  • About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
MPOX
JOIN
Posted on October 17, 2022September 12, 2023

Anaphylaxis V2

This is a revision of the Brighton Collaboration Case Definition of the term “Anaphylaxis” to be utilized in the evaluation of...
Read More
Posted on March 5, 2021September 12, 2023

Anaphylaxis

This post contains the Companion Guide for Anaphylaxis. This and other companion guides have been created as part of the CEPI-fun...
Read More
Posted on August 13, 2007September 14, 2023

Fatigue

Need for developing case definitions and guidelines for fatigue as an adverse event following immunization: Fatiguing illnesses...
Read More
Posted on August 1, 2007October 24, 2023

Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization

To increase comparability of vaccine clinical safety data and to improve the quality of reported data by applying the same criteri...
Read More
Posted on April 13, 2004September 14, 2023

Persistent crying in infants and children as an adverse event following immunization

To improve comparability of vaccine safety data, the Persistent Crying Working Group has developed a case definition and guideline...
Read More
Posted on February 13, 2004September 14, 2023

Fever as an adverse event following immunization

Need for developing case definitions and guidelines for fatigue as an adverse event following immunization: Fatiguing illnesses...
Read More

Recent Posts

  • Standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa feverJune 2, 2025
  • Strengthening Vaccine Safety from Outbreaks to Infants: SPEAC at the World Vaccine CongressMay 27, 2025
  • Brighton Collaboration News — May 2025May 19, 2025
  • Safety by Numbers – February 2025February 19, 2025
  • Brighton Collaboration News — Sept 2024September 9, 2024

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

  • Case Definitions
  • Safety Templates
  • Covid-19
  • Trusted Sources
Linkedin

© Brighton Collaboration  2023. All rights reserved.

  • Disclaimer and Privacy Policy